| OSRX® Prepared Atropine (U.S.N.L.M.) | |||
|---|---|---|---|
| (Myopia prevention) | 1 or 2 drops 0.05%1 qhs (0.5% starting dose used weekly may be appropriate for high rates of progression.2) |
||
| Chem Specs | atropine sulfate 0.01%, 0.025%, 0.05% | ||
| Quantities | 3.5ml | ||
| Cost | 45.00 OSRX® | ||
| Class | anticholinergic | ||
| Action | Competitive antagonist for the muscarinic acetylcholine receptor. | ||
| Myopia Prevention | Reduction in myopia progression is age and dose dependent. (The younger the age the lower the response to given dosage.)3 The 0.05% concentration provides about twice the protective effect as the 0.01% solution1. Rebound after cessation can be avoided with a taper regardless of dosage used4. Although slight mydriasis is present with low dosages5(0.01% to 0.05%), problematic photophobia and cycloplegia is generally absent. With higher concentrations (0.5% or 1%) these side effects should be addressed with progressive and photochromic lenses. |
||
| Increased susceptibility in infants, young children, and in children with blond hair, blue eyes, Down's syndrome, spastic paralysis, or brain damage. |
|||
| Contraindications | Predisposition toward narrow angle glaucoma. Pediatric patients who have previously had a severe systemic reaction to atropine. Hypersensitivity to atropine or product contents. |
||
| Pediatric use | > 3 months | ||
| Pregnancy | Category C | ||
| 0.01% BAK | |||
| Systemic anticholinergics may be associated with increased risk of dementia.6 | |||
2. Polling JR, Tan E, Driessen S, et al. Eye (Lond). 2020 Sep 21.
3. JAMA Ophthalmol; 2021 Jan 14; EPub Ahead of Print; J Wang, Y Li, DC Musch, et. al.
4. Zhu et. al., Efficacy and Safety of 1% Atropine... Int J Med Sci. 2020; 17(2): 176–181.
5. Joachimsen L, Böhringer D, Gross NJ, et al. Ophthalmol Ther. 2019 Jun 12.
6. Risacher, McDonald, Tallman, et al. JAMA April 18, 2016.